
Novavax (NVAX) Stock Forecast & Price Target
Novavax (NVAX) Analyst Ratings
Bulls say
Novavax Inc is experiencing a positive shift in its financial outlook, demonstrated by an increase in its fiscal year 2025 revenue framework, now projected between $1.04 billion and $1.06 billion. The company has recorded $225 million in milestones alongside anticipated earnings of an additional $50 million, indicating strong partnership performance that enhances cash flow and operational funding. Furthermore, Novavax's working capital has improved to $544.7 million, which, combined with reduced expenditures due to cost-saving initiatives, positions the company favorably for future growth and innovation in vaccine development.
Bears say
Novavax Inc. is experiencing notable financial challenges, indicated by a significant decline in cash equivalents from $938.2 million to $778.2 million, attributed to operational cash burn despite receiving milestone payments and proceeds from debt refinancing. The company's year-over-year revenue has decreased by 17%, primarily due to the transfer of lead commercial responsibilities to SNY, which has resulted in reduced commercial infrastructure and a sharp 55% decline in third-quarter revenue. Furthermore, if Novavax's products, such as NanoFlu, do not demonstrate clear differentiation from existing vaccines, the company faces competitive risks that could further hamper its revenue potential and negatively impact future forecasts.
This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.
Novavax (NVAX) Analyst Forecast & Price Prediction
Start investing in Novavax (NVAX)
Order type
Buy in
Order amount
Est. shares
0 shares